Article | February 25, 2019

Real-World Evidence: Explaining The Current State Of The FDA's RWE Program

Source: Ciox Health - Life Sciences

By Paul Roma, CEO, Ciox Health

Research scientist receiving drug approval virtual

Like most instances of adopting new ideas and government programs, few people in drug development have a firm grasp upon and truly understand the FDA’s real-world evidence (RWE) program and the impact it will have on clinical research and trials. This article will guide you through the program and what it means for drug developers and explain the potential that real-world data (RWD) offers in developing RWE to significantly and safely accelerate the drug approval process.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Clinical Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: